⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ARVN News
Arvinas, Inc
Arvinas to Report Second Quarter 2026 Financial Results on August 4, 2026
globenewswire.com
ARVN
Molecular Glues Clinical Trial Landscape: 80+ Emerging Competitors, Pipeline Dynamics, and Future Opportunities | DelveInsight
globenewswire.com
BMY
PFE
AMGN
NVS
MRK
LLY
GILD
AZN
TAK
JNJ
ABBV
CRSP
MOD
ARVN
Form 8-K
sec.gov
ARVN
Entact Bio Appoints John G. Houston, Ph.D., to its Board of Directors
globenewswire.com
ARVN
BMY
Form 8-K
sec.gov
ARVN
Form 8-K
sec.gov
ARVN
Rigel Announces Closing of Licensing Agreement for VEPPANU™ (vepdegestrant)
prnewswire.com
RIGL
ARVN
PFE
Arvinas Joins The Michael J. Fox Foundation’s LITE and PPMI Programs to Advance New Therapies Targeting LRRK2 for Parkinson’s Disease
globenewswire.com
ARVN
Form 8-K
sec.gov
ARVN
Arvinas to Present at Jefferies Global Healthcare Conference
globenewswire.com
ARVN